Stockscreener 앱 받기
64.12
1.07%
0.68
시간 외 거래:
62.97
-1.15
-1.79%
전일 마감가:
$63.44
열려 있는:
$63.9
하루 거래량:
56,836
Relative Volume:
0.80
시가총액:
$1.98B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-84.35
EPS:
-0.7602
순현금흐름:
-
1주 성능:
+2.86%
1개월 성능:
-22.31%
6개월 성능:
+31.07%
1년 성능:
+44.09%
1일 변동 폭
$62.38
$65.90
1주일 범위
$60.00
$65.90
52주 변동 폭
$31.00
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
BLTE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
64.12 | 1.98B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio (NASDAQ:BLTE) Shares Gap UpStill a Buy? - MarketBeat
Facebook, UnitedHealth among Friday's market cap stock movers By Investing.com - Investing.com Nigeria
Facebook, UnitedHealth among Friday's market cap stock movers - Investing.com India
Belite Bio (NASDAQ:BLTE) Trading Down 3.4%What's Next? - MarketBeat
Belite Bio (NASDAQ:BLTE) Shares Down 4.5%Here's What Happened - MarketBeat
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.
Cantor Fitzgerald Predicts Weaker Earnings for Belite Bio - Defense World
FY2024 EPS Estimates for Belite Bio Reduced by HC Wainwright - MarketBeat
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 13.5% in October - MarketBeat
Belite Bio (NASDAQ:BLTE) Given New $110.00 Price Target at Maxim Group - MarketBeat
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year High After Analyst Upgrade - Defense World
Belite Bio stock soars to all-time high of $84.2 amid robust gains - Investing.com UK
Earnings call: Belite Bio reports progress in Tinlarebant trials By Investing.com - Investing.com Australia
Belite Bio shares target boosted, retains buy rating on trial progress - Investing.com
Earnings call: Belite Bio reports progress in Tinlarebant trials - Investing.com
Belite Bio Advances in Retinal Disease Trials - TipRanks
Belite Bio Advances in Tinlarebant Trials, Appoints New CMO - TipRanks
Belite Bio Advances Eye Disease Trials, Posts $109M Cash Position in Q3 Update | BLTE Stock News - StockTitan
Riot Platforms Inc (RIOT-Q) QuotePress Release - The Globe and Mail
Belite Bio (BLTE) Set to Announce Earnings on Tuesday - MarketBeat
Belite Bio (BLTE) Sets Q3 2024 Earnings Call: Key Updates on Retinal Disease Pipeline | BLTE Stock News - StockTitan
Belite Bio stock soars to all-time high of $70.4 amid robust growth - Investing.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Belite Bio Offers New Warrant Opportunities to Investors - TipRanks
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds - ForexTV.com
Nike Inc (NKE-N) QuotePress Release - The Globe and Mail
Belite Bio stock soars to all-time high of $67.6 amid robust gains - Investing.com UK
TSX Smallcap Index (TXTW) QuotePress Release - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Hits New 52-Week HighHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Up 4%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Hits New 12-Month HighHere's Why - MarketBeat
Belite Bio stock soars to all-time high of $56.62 By Investing.com - Investing.com UK
Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality - Yahoo Finance
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - The Bakersfield Californian
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighStill a Buy? - MarketBeat
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit - The Bakersfield Californian
Week in ReviewOctober 5, 2024 - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Hits New 1-Year High at $50.69 - MarketBeat
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Armistice Capital LLC Invests $6.76 Million in Belite Bio, Inc (NASDAQ:BLTE) - MarketBeat
Servicenow Inc (NOW-N) QuotePress Release - The Globe and Mail
International companies to host live webcasts at Deutsche - GlobeNewswire
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 5.1% in August - MarketBeat
Belite Bio (NASDAQ:BLTE) Rating Reiterated by HC Wainwright - Defense World
Belite Bio shares hold buy rating, steady target on trial progress - Investing.com
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease - StockTitan
Belite Bio Welcomes New Chief Medical Officer - TipRanks
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):